Enrica Morra
Enrica Morra
Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milano
Verified email at ospedaleniguarda.it
TitleCited byYear
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at …
CL Sawyers, A Hochhaus, E Feldman, JM Goldman, CB Miller, ...
Blood 99 (10), 3530-3539, 2002
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ...
Blood 113 (13), 2895-2901, 2009
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
RG Owen, SP Treon, A Al-Katib, R Fonseca, PR Greipp, ML McMaster, ...
Seminars in oncology 30 (2), 110-115, 2003
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ...
New England Journal of Medicine 369 (2), 111-121, 2013
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and …
F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ...
Blood 115 (9), 1703-1708, 2010
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
Italian Cooperative Study Group on Chronic Myeloid Leukemia
New England Journal of Medicine 330 (12), 820-825, 1994
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti, E Rumi, E Pungolino, L Malabarba, P Bertazzoni, ...
The American journal of medicine 117 (10), 755-761, 2004
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
R Cairoli, A Beghini, G Grillo, G Nadali, F Elice, CB Ripamonti, ...
Blood 107 (9), 3463-3468, 2006
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ...
Journal of the National Cancer Institute 103 (7), 553-561, 2011
C-kit mutations in core binding factor leukemias
A Beghini, P Peterlongo, CB Ripamonti, L Larizza, R Cairoli, E Morra, ...
Blood 95 (2), 726-728, 2000
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele …
L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ...
Blood 121 (11), 2051-2058, 2013
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
C Cesana, C Klersy, L Barbarano, AM Nosari, M Crugnola, E Pungolino, ...
Journal of Clinical Oncology 20 (6), 1625-1634, 2002
Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology
EP Alessandrino, S Amadori, G Barosi, M Cazzola, A Grossi, LN Liberato, ...
haematologica 87 (12), 1286-1306, 2002
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia
MA Dimopoulos, MA Gertz, E Kastritis, R Garcia-Sanz, EK Kimby, ...
J Clin Oncol 27 (1), 120-126, 2009
Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration
G Alimena, E Morra, M Lazzarino, AM Liberati, E Montefusco, D Inverardi, ...
Blood 72 (2), 642-647, 1988
Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies
M Montillo, T Hamblin, M Hallek, E Montserrat, E Morra
haematologica 90 (3), 391-399, 2005
Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients
G Visani, C Finelli, U Castelli, MC Petti, P Ricci, N Vianelli, L Gianni, ...
British journal of haematology 75 (1), 4-9, 1990
Splenic marginal zone lymphoma: a prognostic model for clinical use
L Arcaini, M Lazzarino, N Colombo, S Burcheri, E Boveri, M Paulli, ...
Blood 107 (12), 4643-4649, 2006
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
S Verstovsek, HM Kantarjian, Z Estrov, JE Cortes, DA Thomas, T Kadia, ...
Blood 120 (6), 1202-1209, 2012
Mucormycosis in hematologic malignancies: an emerging fungal infection
A Nosari, P Oreste, M Montillo, G Carrafiello, M Draisci, G Muti, A Molteni, ...
Haematologica 85 (10), 1068-1071, 2000
The system can't perform the operation now. Try again later.
Articles 1–20